Author: Bill Snyder
VUMC team puts tool to reduce heart failure admissions to test
Nov. 11, 2021—Vanderbilt researchers have developed a risk stratification tool to predict outcomes and avoid unnecessary hospital admissions after emergency department visits for acute heart failure.
New way to bEET insulin resistance
Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Translational Research Forum honors scientific excellence
Nov. 11, 2021—Vanderbilt University Medical Center’s strength in translational research, which helps “translate” scientific discovery into medical practice, was celebrated recently during the Vanderbilt Translational Research Forum
Zost honored for research on COVID-19, other life-threatening viral diseases
Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases.
Nominations being accepted for 2022 Vanderbilt Prize
Oct. 18, 2021—Nominations for the 2022 Vanderbilt Prize in Biomedical Science are now being accepted.
New marker for metaplasia
Oct. 14, 2021—A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.
STAR Clinical Research Network to receive major grant renewal
Oct. 14, 2021—Vanderbilt's STAR Clinical Research Network has been approved for an additional $8.9 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) to support its efforts to improve health care throughout the Southeast and across the United States.
AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC
Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
VUMC research contributed to first COVID-19 pill now under review
Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.
Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture
Sep. 29, 2021—Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7.
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
VUMC team to test personalized acute heart failure treatment
Sep. 16, 2021—Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.
